AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Business & Industry
- Abbott names Robert B. Ford president, chief operating officer
- Boehringer Ingelheim increases awareness of health with the micro enterprise project 'Elephants' in South India
- Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
- Bristol-Myers Squibb and Compugen announce clinical collaboration to evaluate therapeutic regimen in advanced solid tumors
- Up to 10-years of follow-up data reaffirm safety profile of Mavenclad (cladribine tablets)
Research & Development
- Cancer stem cells use normal genes in abnormal ways
- Organs-on-chip technology reveals new drug candidates for Lou Gehrig's disease
- Seed oils are best for LDL cholesterol
- Could treating psoriasis in the future be as easy as going online?
- Evidence mounts linking aspirin to lower risk of ovarian cancer
- Health-related quality of life overlooked in cancer drug studies
- The Nobel Prize in Physiology or Medicine 2018 was awarded jointly to James P. Allison and Tasuku Honjo "for their discovery of cancer therapy by inhibition of negative immune regulation."
Conferences & Events
- SMi Group announces the 10th Annual RNA Therapeutics Conference
- Pre-Filled Syringes & Injectable Drug Devices Europe 2018
- Social Media in the Pharmaceutical Industry Conference 2019
- Lyophilization USA Conference 2018
- SMi presents the 13th annual industry leading conference: Cold Chain Distribution
- Orphan Drugs and Rare Diseases Conference 2018
- Immuno-Oncology Conference 2018
Regulatory Affairs
- FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old
- FDA approves first treatment for advanced form of the second most common skin cancer
- FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
- FDA approves new kind of treatment for hairy cell leukemia
- FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease